GlassScriptPhysician profile
Sunil K Narla
NPI 1588866636
$6,705.71
in general payments reported to CMS, 2019-2025
30 companies · $582 in 2025
The $582 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $755 · 2021: $1,092 · 2022: $1,317 · 2023: $889 · 2024: $765 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,006.44 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $968.74 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $886.36 | 2019-2025 | |
| Pfizer INC. | $760.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $654.79 | 2019-2022 | |
| Abbvie INC. | $408.32 | 2021-2025 | |
| Electromed, INC. | $304.76 | 2019-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $244.89 | 2019-2024 | Dificid |
| Paratek Pharmaceuticals, INC. | $227.85 | 2020-2024 | Nuzyra |
| Philips North America LLC | $209.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.46 | 2022-2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.53 | 2022-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $94.18 | 2021-2023 | Ultomiris |
| Allergan, INC. | $75.96 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $75.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $75.39 | 2019 | |
| Abbott Laboratories | $71.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.80 | 2019-2025 | Eliquis |
| Melinta Therapeutics, LLC | $47.97 | 2020-2021 | |
| Insmed, INC. | $43.22 | 2023 | Arikayce |
| Lundbeck LLC | $42.43 | 2019 | |
| Novo Nordisk INC | $40.68 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $32.59 | 2019 | |
| Gilead Sciences, INC. | $31.26 | 2023 | Veklury |
| Portola Pharmaceuticals, LLC | $23.13 | 2019 | |
| Nabriva Therapeutics, Plc | $21.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.49 | 2025 | |
| Medtronic, INC. | $18.37 | 2021 | |
| Lilly USA, LLC | $14.12 | 2019 | |
| Smith+Nephew, INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Narla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.